Please assess the completion status of the following clinical trial:

Trial Title: Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol~* Male or female between, and including, 18 and 21 months of age at the time of booster vaccination.~* Subjects who received three doses of pneumococcal conjugate vaccine in study NCT00808444~* Written informed consent obtained from the parents/LAR(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding vaccination, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.~* A family history of congenital or hereditary immunodeficiency.~* Administration of immunoglobulins and/ or any blood products within the 3 months preceding vaccination or planned use during the study period.~* Administration of any pneumococcal and/or vaccine containing diphtheria, tetanus, pertussis, poliomyelitis or Haemophilus influenzae type b antigens since the end of study NCT00808444.~* Planned administration/administration of a vaccine not foreseen by the study protocol during the study period starting from 30 days before vaccination and ending 30 days after vaccination.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* History of any reaction or allergic disease likely to be exacerbated by any component of the study vaccines.~* Known hypersensitivity to any component of the study vaccines including anaphylactic reactions following the administration of the study vaccines.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures. (Subjects who have had a single uncomplicated febrile convulsion in the past can be included)~* Fever at the time of vaccination.~  * Fever is defined as rectal temperature \>= 38.0°C or tympanic/axillary/ oral temperature \>= 37.5°C.~* Acute disease at the time of enrolment.~  * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.~* Child in care.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 21 Months
- Healthy Volunteers: t

Study Arms:
- Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group (Type: EXPERIMENTAL): children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
- Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group (Type: ACTIVE_COMPARATOR): children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete